162 related articles for article (PubMed ID: 22768321)
21. Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis.
Denecke A; Iftner T; Iftner A; Riedle S; Ocak M; Luyten A; Üye I; Tunc K; Petry KU
BMC Infect Dis; 2021 Jul; 21(1):634. PubMed ID: 34215215
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
Murillo R; Ordóñez-Reyes C
Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
[TBL] [Abstract][Full Text] [Related]
23. Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol.
Murenzi G; Shumbusho F; Hansen N; Munyaneza A; Gage JC; Muhoza B; Kanyabwisha F; Pierz A; Tuyisenge P; Anastos K; Castle PE
BMJ Open; 2022 Aug; 12(8):e061650. PubMed ID: 36008069
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.
Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T
Front Public Health; 2023; 11():1204101. PubMed ID: 37719724
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I;
J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of human papillomavirus genotypes in high-grade cervical precancer and invasive cervical cancer from cancer registries before and after vaccine introduction in the United States.
Mix JM; Saraiya M; Thompson TD; Querec TD; Greek A; Tucker TC; Peters ES; Lynch CF; Hernandez BY; Copeland G; Goodman MT; Unger ER
Cancer; 2021 Oct; 127(19):3614-3621. PubMed ID: 34289090
[TBL] [Abstract][Full Text] [Related]
27. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
29. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
30. Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches.
Donken R; Hoes J; Knol MJ; Ogilvie GS; Dobson S; King AJ; Singer J; Woestenberg PJ; Bogaards JA; Meijer CJLM; de Melker HE
BMC Infect Dis; 2020 Jul; 20(1):482. PubMed ID: 32640998
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus (HPV) vaccines: a Canadian update.
Foerster V; Murtagh J
Issues Emerg Health Technol; 2007 Dec; (109):1-8. PubMed ID: 18062141
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
[TBL] [Abstract][Full Text] [Related]
33. Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction.
Widdice LE; Bernstein DI; Franco EL; Ding L; Brown DR; Ermel AC; Higgins L; Kahn JA
Vaccine; 2019 Oct; 37(45):6832-6841. PubMed ID: 31582269
[TBL] [Abstract][Full Text] [Related]
34. Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination.
Lehtinen T; Söderlund-Strand A; Petäjä T; Eriksson T; Jokiranta S; Natunen K; Dillner J; Lehtinen M
J Infect Dis; 2017 Nov; 216(8):966-968. PubMed ID: 28968844
[TBL] [Abstract][Full Text] [Related]
35. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy.
Brotherton JM; Kaldor JM; Garland SM
Sex Health; 2010 Sep; 7(3):310-9. PubMed ID: 20719220
[TBL] [Abstract][Full Text] [Related]
36. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries.
Wong CA; Saraiya M; Hariri S; Eckert L; Howlett RI; Markowitz LE; Brotherton JM; Sinka K; Martinez-Montañez OG; Kjaer SK; Dunne EF
Vaccine; 2011 Jan; 29(5):878-85. PubMed ID: 20971113
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of using composite HPV genotyping assay results to monitor human papillomavirus infection burden through simulation.
Lin CY
BMC Infect Dis; 2015 Mar; 15():123. PubMed ID: 25880688
[TBL] [Abstract][Full Text] [Related]
38. Regional variations in human papillomavirus prevalence across time in NHANES (2003-2014).
Hirth JM; Kuo YF; Starkey JM; Rupp RE; Laz TH; Rahman M; Berenson AB
Vaccine; 2019 Jul; 37(30):4040-4046. PubMed ID: 31182324
[TBL] [Abstract][Full Text] [Related]
39. Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men.
Lin A; Ong KJ; Hobbelen P; King E; Mesher D; Edmunds WJ; Sonnenberg P; Gilson R; Bains I; Choi YH; Tanton C; Soldan K; Jit M
Clin Infect Dis; 2017 Mar; 64(5):580-588. PubMed ID: 28011615
[TBL] [Abstract][Full Text] [Related]
40. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
